

Press Release 2014-04-09

THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION OF THE INFORMATION SHOULD NOT BE COMPATIBLE WITH APPLICABLE REGULATIONS

Enzymaticas rights issue oversubscribed

Enzymatica AB (publ) ("Enzymatica" or the "Company") has completed the rights issue of shares as decided by the Board on 16 February 2014 approved by the general meeting held on the 6 March 2014. The subscription period ran during the period the 17 March to 2 April 2014. The Rights Issue has been fully subscribed and provides the Company with approximately SEK 63.3 million SEK before deducting issue expenses. The Board has also decided to fully exploit the over-allotment option of up to 1.5 million shares, which means that the Company will receive an additional approximately SEK 20.3 million. Hence, in total the Company thus raises approximately SEK 83.6 million before issue expenses.

The rights issue was subscribed to 82.3 percent with subscription rights and the remainder, representing 17.7 percent, without subscription rights. Total applications for subscription without subscription rights amounted to 54.3 percent of the issue. In relation to the shares newly issued under the rights issue, this corresponds to a subscription level of 136.6 percent. Since the rights issue was oversubscribed, no underwriting will be utilized.

In view of the oversubscription of the issue, the Board has decided to make full use of over-allotment option, which means that the Board, pursuant to the authorization from the extraordinary shareholders' meeting on the 6 March 2014, has decided to issue an additional 1.5 million shares at an issue price of 13.50 SEK. The issue is fully subscribed by the oversubscription.

The rights issue provides the Company with approximately SEK 63.3 million and the over-allotment option adds approximately SEK 20.3 million. Hence, in total the Company thus raises approximately SEK 83.6 million before issue expenses.

"We are delighted that both existing and new shareholders have shown us confidence. The capital raised will allow us to continue to build the company. According to plan, we can now expand geographically, launch new products and continue our efforts in research and development", said Michael Edelborg Christensen, CEO Enzymatica.

Allotment of shares subscribed for without subscription rights under the rights issue has been in accordance with the principles set out in the prospectus dated 10 March 2014. Allocation of shares under the over-allotment option has also been allocated in accordance with the same principles as in the rights issue. Notification of the allotment is made by a contract note posted to respective subscriber. Shares shall be paid in accordance with the instructions on the contract note.

The rights issue and over-allotment option increases the share capital of Enzymatica with 247 691.56 SEK through the issue of 6,192,287 shares. After the new issues, the number of shares in the Company is 24,961,438 shares. The share capital amounts to 998 457.84 SEK after the new issues.

Paid subscription shares (BTA) in the rights issue is traded on AktieTorget during the short name ENZY BTA until the issue has been registered by the Bolagsverket and will then be replaced by shares. This is expected to occur during the second half of April 2014. In connection with this, the new shares will be admitted for trading on AktieTorget.

Subscribers who have received allotment of shares under the over-allotment option will receive paid subscription shares (BTA) other than those subscribed under the rights issue. BTA obtained under the over-allotment option will be traded on the Stock Market during the short name ENZY BTA 2 and 15 April 2014, and they will also be replaced by shares in connection with the issue have been registered by Bolagsverket, which is expected to occur at the same time as above, ie in the second half of April 2014. In connection with this, the new shares will be admitted for trading on AktieTorget.

Please note that subscribers who have received allotment under the rights issue as well as registered, all BTAs will be replaced by shares and these shares will be of the same kind.

Advisors

Erik Penser Ltd has acted as financial advisor and Mannheimer Swartling LLP acted as legal advisor to Enzymatica .

For more information about Enzymatica, please contact:

Michael Edelborg Christensen , CEO Enzymatica AB (publ) , 0768-14 41 66 ,
michael.christensen@enzymatica.se

*Enzymatica AB (publ) discloses this information pursuant to the Securities Markets Act.
The information was submitted for publication April 9, 2014 at 08.30.*

About Enzymatica AB (publ)

Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and sales of medical device products based on a patented enzyme technology. Enzymatica has several projects in the pipeline for diseases of the skin, throat and mucous membranes. Enzymatica has two registered medical device products, PeriZyme® Chewing Gum CE, against oral cavity diseases and ColdZyme® Mouth Spray CE against the common cold, the latter recently launched throughout the country.

About Enzymatica online

[Enzymatica's press room »](#)

[Enzymatica's website »](#)

[Enzymatica on LinkedIn »](#)

[Enzymatica on twitter »](#)

[For Investors »](#)

[For Investors »](#)

[ColdZyme website »](#)

[ColdZyme on facebook »](#)

IMPORTANT INFORMATION

The information herein is not an offer to acquire, subscribe for or otherwise trade in shares, subscription rights or other securities in Enzymatica.

This press release is not for release, publication or distribution, directly or indirectly, in or into the United States or other jurisdiction where such action is wholly or partially subject to legal restrictions, or would require additional prospectuses, registration or other measures than those required by Swedish law. The information contained in this press release may not be forwarded or reproduced in any way that is in conflict with such restrictions or would such requirements. Actions in violation of this instruction may constitute a violation of applicable securities laws.

No subscription rights, paid subscription shares or shares has been, and will not be registered under the United States Securities Act of 1933 ("Securities Act") or the securities laws of any state or other jurisdiction of the United States and may not be offered , subscribed, exercised, pledged, sold, resold, delivered or transferred, directly or indirectly, within the United States.

This press release may contain certain forward- looking statements that reflect Enzymaticas current views of future events and financial and operational performance. Words such as "intends", "anticipates", "expects" , "may" , "plan " , "anticipate" or similar expressions regarding indications or predictions of future developments or trends, and are not based on historical facts , constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties because it is dependent on future events and circumstances. Forward-looking statements are not guarantees regarding future results or developments and actual results may differ materially from those set forth in forward-looking information.